Let’s dive in. Semaglutide is in a class called glucagon-like peptide-1 (GLP-1) receptor agonists. It works by mimicking GLP-1, a hormone the intestines naturally make. GLP-1 plays a key role in ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Half received semaglutide, a type of GLP-1 receptor agonist, while the other half received no treatment. Over the nine-week trial, participants taking semaglutide started at a dose of 0.25 mg per ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

The Food and Drug Administration (FDA) on Friday announced that semaglutide, the active ingredient ... wellness company that sells compounded GLP-1 medications, plummeted 25% on Friday.

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

The drug — the brand name for the GLP-1 agonist semaglutide — “significantly reduced weekly alcohol craving,” according to a study published Wednesday, Feb. 12, in the Journal of the ...

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

This came after Hetero Labs presented the BE study protocol, vide no. AZBE112405, Version No. 01, Dated 15.11.2024 and the ...

In this review of 37.1 million patients, the incidence rate of NAION among semaglutide users was 14.5 and 8.7 per 100,000 person-years using the sensitive and specific NAION definitions ...

Adults with type 1 diabetes had greater declines in HbA1c and body weight 1 year after being prescribed semaglutide or tirzepatide. Randomized controlled trials are needed to assess efficacy and ...